From Customer-centric User Research to Data Visualization App:

A Journey of Developing Modules to Support Exploratory Biomarker Analysis

Benjamin Lang & Stefan Döring







The views expressed in this talk are those of the speakers and not necessarily those

of Boehringer Ingelheim



Background: Generalized Pustular Psoriasis (GPP)

- Rare, potentially life-threatening skin disease
- Characterized by episodes of widespread eruption of sterile visible pustules
- Can occurr with or without systemic inflammation
- Flares are characteristic of the clinical course




Background: Spesolimab

- In GPP the IL-36 pathway plays a key role
- Inhibition of IL-36 signaling may provide effective targeted treatment
- Spesolimab is a IL-36 receptor inhibitor to treat GPP



Effisayil[™] 1 - Spesolimab in Generalized Pustular psoriasis




Source: N Engl J Med 2021; 385:2431-2440, DOI: 10.1056/NEJMoa2111563 Figure S1 in Supplementary Appendix, slightly modified for the purpose of this presentation

Evidence of effectiveness

Binary efficacy endpoint

Spesolimab rapidly controlled symptoms of GPP flare skin within 1 week of treatment



• Continuous efficacy endpoint

Role of Biomarkers

- Provide strong mechanistic support
- Provide further insights into GPP disease and mode of action of spesolimab
- Biomarker focused presentations and publications

Protein Biomarker Analysis and Visualization

Objectives

- Multiple protein biomarkers (from various pathways) should be analyzed and visualized
- Link to main clinical efficacy endpoint(s) should be presented
- Integration of relevant baseline variables and/or other binary efficacy endpoints of interest



Protein Biomarker Analysis and Visualization

Objectives

- Multiple protein biomarkers (from various pathways) should be analyzed and visualized → heatmap
- Link to main clinical efficacy endpoint(s) should be presented → sorting of patients via waterfall plot
- Integration of relevant baseline variables and/or other binary efficacy endpoints of interest → extra panels



Variety of options for the implementation


- Which biomarkers to be integrated and how to order?
- What clinical, baseline and/or subgroup features should be integrated?
- Which time point(s) are most important?
- What scaling and coloring is most suitable?
- Should certain patients be excluded (e.g. due to unavailability of data)?
- What kind of labels are required?




WHY? - Motivation



10



statistical novelties




- Web-based
- Linked outputs
- Real-time and interactive

Effective & focused trial oversight


- Review, incl. deep-dive option
- Align & share insights during meetings
- Faster clinical insights generation and more agile decision making






Boehringer Ingelheim

From Customer-centric User Research to Data Visualization App



Boehringer Ingelheim

From Customer-centric User Research to Data Visualization App



Boehringer Ingelheim


The Concept of the Modular Approach

- DaVinci Modules are functional building blocks composable into customized Apps
- This customization enables the building of Apps according to trial and project-specific needs
- Enables teams to use best-practice templates with a common look-and-feel
- The Hosting Platform allows to create, integrate and deploy Apps.






Modular Approach: Data Selection






Modular Approach: Subject filtering by Contineous Variable






Modular Approach: Subject filtering by Categorical Variable





Modular Approach: The Clinical Timelines Module





Modular Approach: The Patient Profile Module

DaVinci X	Disposition	Clinical Timelines	AE Hierarchy Table	Patient Profile	AE Table							8	
set Selection	Select Patient I	D:											
MO 2 •	01-701-1015		*										
	Patient In	formation											
	Study Site Iden	ntifier : 701			∎:63			ex:F	11 M.S. 10				
of 200 total entries selected	Race : WHITE RFICDT : 2014-			Ethnicity : HISPANIC OR LATINO Date of First Exposure to Treatment : 2014-01-02				escription of Planned ate of Last Exposure t	to Treatment : 20				
Remove Fillens +	Date of Discon	tinuation/Completion : 20	14-07-02	Rea	ason for Discontinuation : Complete	d	A	ctual Treatment for Pe	riod 01 : Placebo	0			
Clear All Filters	Data Tak	e											
	Data Tabl												
		Is Conconmitant Medic			D								
			itton Lab vitalis	gns									
	Select Extra Co												
	USUBJID, AS	TDT, AENDT, AEDECOD, A	.ε. -										
	Reset Column	ns Order											
								Se	Search	τ.			
	Uniqu								Action Taker	n			
	Unique Subjection	Analysis Start	Analysis End Date	Dictionary- Derived Term	Primary System Organ Class	Severity/Intensity	Serious	Causality	with Study		Outcome		E
	Subjec	Analysis Start		Dictionary- Derived Term	Primary System Organ Class	Severity/Intensity	Serious Event	Causality				of Adverse ent	E.
	Subjec Identifi	er Date	Date	Derived Term	All	Ali	Event	Al	with Study Treatment		All	ent	
	Subjec	er Date	Date	Derived Term			Event		with Study Treatment			ent	
	Subjec Identifi	et Analysis Start Date All 1015 2014-01-03	Date	Derived Term All APPLICATION SITE	All GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	Ali	Event	Al	with Study Treatment			ent DVERED/N IOLVED	10.
	Subjec Identifi All 1 01-701-	tt Analysis Start er Date All 1015 2014-01-03 1015 2014-01-03	Date	Derived Term All All APPLICATION SITE ERYTHEMA APPLICATION SITE	All GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS GENERAL DISORDERS AND ADMINISTRATION SITE	All	Event All N	All PROBABLE	with Study Treatment			overed/N iolved	10
	Subjec Identifi 1 01-701- 2 01-701-	tt Analysis Start er Date All 1015 2014-01-03 1015 2014-01-03 1015 2014-01-09	Date All	Derived Term	All GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS GASTROINTESTINAL	All MILD MILD	Event AB N N	All PROBABLE PROBABLE	with Study Treatment		All NOT RECI RES	overed/N iolved	10
	Subjection identifi 1 01-701- 2 01-701- 3 01-701-	tt Analysis Start Date Date 1015 2014-01-03 1015 2014-01-03 1015 2014-01-03 1015 2014-01-03 010 2014-01-03	Date All	Derived Term	All GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS GASTROINTESTINAL	All MILD MILD	Event AB N N	All PROBABLE PROBABLE	with Study Treatment		All NOT RECI RES	overed/N iolved	10




Modular Approach: The Patient Profile Module

-					n/app_papo-clinlines-d						A 16 0			
DaVinci	×	Disposi	1990) - 21 <u>1</u>	inical Timelines	AE Hierarchy Table	Patient Profile	AE Table						9	
et Selection		Select Pat												
/IO 2	•	01-701-1	015		*									
		Patien	t Inform	ation										
e			Identifier :			Ag	e:63		s	ex:F				
of 200 total entries selected		Race : WH RFICDT : 2				Ethnicity : HISPANIC OR LATINO Date of First Exposure to Treatment : 2014-01-02 Reason for Discontinuation : Completed				Description of Planned Arm : Placebo Date of Last Exposure to Treatment : 2014-07-02 Actual Treatment for Period 01 : Placebo				
/ Remove Filters				on/Completion : 20	14-07-02									
Clear All Filters		Data T	able											
		Select Dor												
		-		onconmitant Medica	ation Lab Vital si	ans	C							
		Select Ext	ra Columns											
		USUBJIC	, ASTDT, AB	ENDT, AEDECOD, A	κε -									
		Reset Co	olumns Orde	r										
											Se	Search:		
		S	nique ubject entifier	Analysis Start Date	Analysis End Date	Dictionary- Derived Term	Primary System Organ Class	Severity/Intensity	Serious Event	Causality	Action Taken with Study Treatment	Outcome of Ever		
		All		Alt	All	All	All	All	All	All	All	All		
		1 01	701-1015	2014-01-03		APPLICATION SITE ERYTHEMA	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	MILD	Ν	PROBABLE		NOT RECOV RESC		
		2 01	701-1015	2014-01-03		APPLICATION SITE PRURITUS	GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	MILD	N	PROBABLE		NOT RECOV RESO		
		3 01-	701-1015	2014-01-09	2014-01-11	DIARRHOEA	GASTROINTESTINAL DISORDERS	MILD	N	REMOTE		RECOVERED	/RESOLVE	
		Showing 1	to 3 of 3 ent	ries										



Modular Approach: Bookmark functionality





Backup (App demo)




n DaVinci X	WF+HM	8 0 :
Filters ▼ 53 of 53 total entries selected Add / Remove Filters ■ Clear All Filters	This is a NonGXP module Watersall Con/Cat Param. Heatmap Outlier	
	Use parameter Value TRTPN [Planned Treatment (N)] Grouping STUDYID [Study Identifier] TRTPN Min Max Max Jack Study Jack Stu	CDISCPILOT01 CDISCPILOT01 CDISCPILOT01




n DaVinci X	WF+HM	S 🕫
Filters	This is a NonGxP module Waterfall Con/Cat Param. Heatmap Outlier Outle Cotice Outle Outle Cotice Outle Outle Cotice Outle Outle Cotice Outle Outle Cotice Outle </td <td>Active Active Active</td>	Active Active Active



















🚺 DaVinci 🗙	WF+HM	S 08
Filters ▼ 53 of 53 total entries selected	This is a NonGxP module	
Add / Remove Filters	Outlier NaGE numeric Age AGEGR1 character Pooled Age Group 1 NaGE numeric Pooled Age Group 1 NaGE character Pooled Age Group 1 NaGE character Pooled Age Group 1 NaGE character Active Placeb Pl	Active
	ARM character Planned Treatment Ik AVGDD numeric Avg Daily Dose (as planned) Ik BMIBL numeric (1 missing) Baseline BMI (Roym*2) BMIBLGR1 character Pooled Baseline BMI Group 1	Y
	COMP16FL character Completers of Week 16 Population Flag COMP24FL character Completers of Week 24 Population Flag COMP8FL character Completers of Week 24 Population Flag DCDECOD character Standardized Disposition Term DCREASCD character Reason for Discontinuation DISCONFL character DistonstT bate	2 0 -2

🕐 DaVinci 🗲	<	WF+HM Ø	\$
Filters Y 53 of 53 total entries selected		This is a NonGxP module	
Add / Remove Filters -	0	Waterfall Con/Cat Param. Heatmap Outlier vigeopeld vi	
		Biomarker 1 Biomarker 10 Biomarker 10 Biomarker 12 Biomarker 13 Biomarker 14 Biomarker 14 Biomarker 14 Biomarker 14 Biomarker 14 Biomarker 15 Biomarker 14 Biomarker 15 Biomarker 14 Biomarker 14 Biomarker 15 Biomarker 14 Biomarker 15 Biomarker 15 Biomarker 16 Biomarker 16 Biomarker 17 Biomarker 18	4 2 0 -2

